title: Up-regulation of striatal adenosine A(2A) receptors with iron deficiency in rats: effects on locomotion and cortico-striatal neurotransmission.
abstract: Brain iron deficiency leads to altered dopaminergic function in experimental animals, which can provide a mechanistic explanation for iron deficiency-related human sensory-motor disorders, such as Restless Legs Syndrome (RLS). However, mechanisms linking both conditions have not been determined. Considering the strong modulation exerted by adenosine on dopamine signaling, one connection could involve changes in adenosine receptor expression or function. In the striatum, presynaptic A(2A) receptors are localized in glutamatergic terminals contacting GABAergic dynorphinergic neurons and their function can be analyzed by the ability of A(2A) receptor antagonists to block the motor output induced by cortical electrical stimulation. Postsynaptic A(2A) receptors are localized in the dendritic field of GABAergic enkephalinergic neurons and their function can be analyzed by studying the ability of A(2A) receptor antagonists to produce locomotor activity and to counteract striatal ERK1/2 phosphorylation induced by cortical electrical stimulation. Increased density of striatal A(2A) receptors was found in rats fed during 3 weeks with an iron-deficient diet during the post-weaning period. In iron-deficient rats, the selective A(2A) receptor antagonist MSX-3, at doses of 1 and 3 mg/kg, was more effective at blocking motor output induced by cortical electrical stimulation (presynaptic A(2A) receptor-mediated effect) and at enhancing locomotor activation and blocking striatal ERK phosphorylation induced by cortical electrical stimulation (postsynaptic A(2A) receptor-mediated effects). These results indicate that brain iron deficiency induces a functional up-regulation of both striatal pre- and postsynaptic A(2A) receptor, which could be involved in sensory-motor disorders associated with iron deficiency such as RLS.
authors.affiliation: National Institute on Drug Abuse, IRP, NIH, DHHS, Baltimore, MD 21224, USA. quirozc@mail.nih.gov
authors.forename: César
authors.initials: C
authors.lastname: Quiroz
authors.forename: Virginia
authors.initials: V
authors.lastname: Pearson
authors.forename: Seema
authors.initials: S
authors.lastname: Gulyani
authors.forename: Richard
authors.initials: R
authors.lastname: Allen
authors.forename: Christopher
authors.initials: C
authors.lastname: Earley
authors.forename: Sergi
authors.initials: S
authors.lastname: Ferré
mesh_terms: D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D015153:Blotting, Western; D002540:Cerebral Cortex / Q000187:drug effects / Q000502:physiology*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004558:Electric Stimulation; D004576:Electromyography; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D000090463:Iron Deficiencies; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D009434:Neural Pathways / Q000187:drug effects / Q000502:physiology; D010766:Phosphorylation / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043705:Receptor, Adenosine A2A / Q000378:metabolism*; D011990:Receptors, Transferrin / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology; D014970:Xanthines / Q000494:pharmacology
chemical_list: D058917:Adenosine A2 Receptor Antagonists; C113602:MSX 3 compound; D043705:Receptor, Adenosine A2A; D011990:Receptors, Transferrin; D014970:Xanthines
references.citation: Trends Neurosci. 1997 Oct;20(10):482-7
references.pmid: 9347617
references.citation: Brain. 2009 Sep;132(Pt 9):2403-12
references.pmid: 19467991
references.citation: Neurology. 1999 Mar 23;52(5):1060-3
references.pmid: 10102429
references.citation: Pharmacol Rev. 2001 Dec;53(4):527-52
references.pmid: 11734617
references.citation: Semin Pediatr Neurol. 2006 Sep;13(3):158-65
references.pmid: 17101454
references.citation: J Neurosci. 2006 Feb 15;26(7):2080-7
references.pmid: 16481441
references.citation: J Comp Neurol. 1998 Nov 16;401(2):163-86
references.pmid: 9822147
references.citation: Early Hum Dev. 2002 Dec;70(1-2):85-101
references.pmid: 12441207
references.citation: J Nutr. 2008 Dec;138(12):2487-94
references.pmid: 19022977
references.citation: Prog Neurobiol. 2007 Dec;83(5):277-92
references.pmid: 17646043
references.citation: Sleep Med. 2003 Mar;4(2):101-19
references.pmid: 14592341
references.citation: Curr Pharm Des. 2008;14(15):1468-74
references.pmid: 18537670
references.citation: Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):409-18
references.pmid: 11509198
references.citation: Brain Res Rev. 2007 Aug;55(1):55-67
references.pmid: 17408563
references.citation: Pharmacol Biochem Behav. 1980 Apr;12(4):493-502
references.pmid: 7393950
references.citation: Annu Rev Nutr. 2003;23:41-58
references.pmid: 12704220
references.citation: Arch Intern Med. 2005 Jun 13;165(11):1286-92
references.pmid: 15956009
references.citation: Br J Phys Med. 1954 Jul;17(7):160-2
references.pmid: 13172443
references.citation: Neuropsychopharmacology. 2003 Jul;28(7):1281-91
references.pmid: 12700682
references.citation: J Nutr. 1997 Dec;127(12):2282-8
references.pmid: 9405575
references.citation: Sleep Med. 2006 Aug;7(5):458-61
references.pmid: 16740411
references.citation: J Nutr. 2000 Nov;130(11):2831-7
references.pmid: 11053528
references.citation: Parkinsonism Relat Disord. 2004 Jul;10(5):265-71
references.pmid: 15196504
references.citation: Adv Biochem Psychopharmacol. 1983;37:309-21
references.pmid: 6138953
references.citation: Sleep Med. 2004 Jul;5(4):385-91
references.pmid: 15222997
references.citation: J Neurosci. 2006 Oct 18;26(42):10808-12
references.pmid: 17050719
references.citation: Neurology. 2000 Apr 25;54(8):1698-700
references.pmid: 10762522
references.citation: Biol Signals Recept. 1998 May-Jun;7(3):157-78
references.pmid: 9672759
references.citation: J Neurosci. 2002 Jun 15;22(12):5042-54
references.pmid: 12077200
references.citation: J Nutr. 2003 May;133(5 Suppl 1):1468S-72S
references.pmid: 12730445
references.citation: ScientificWorldJournal. 2009 Nov 18;9:1321-44
references.pmid: 19936569
references.citation: Neuropsychopharmacology. 2009 Mar;34(4):972-86
references.pmid: 18800071
references.citation: Exp Neurol. 2009 Feb;215(2):236-42
references.pmid: 19013457
references.citation: Neurology. 2004 May 11;62(9):1563-7
references.pmid: 15136682